- Exchange: Frankfurt
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Ariad Pharmaceuticals Inc
+ Add to WatchlistAPS:GR
13.230 EUR 0.320 2.48%As of 13:18:44 ET on 05/21/2013.
Snapshot for Ariad Pharmaceuticals Inc (APS)
| Open: | 12.720 | Day's Range: | 12.716 - 13.250 | Volume: | 350 |
|---|---|---|---|---|---|
| Previous Close: | 12.910 | 52wk Range: | 12.165 - 20.000 | 1-Yr Rtn: | +0.61% |
Key Statistics for APS
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. DAX | - |
| Earnings Per Share (USD) (ttm) | - |
| Est. EPS (USD) (12/2013) | -1.6460 |
| Est. PEG Ratio | - |
| Market Cap (M EUR) | 0.00 |
| Shares Outstanding (M) | 0.00 |
| 30 Day Average Volume | 755 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/02/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for APS
Company Profile & Key Executives for APS
ARIAD Pharmaceuticals, Inc. is a global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. The Company's approach to structure-based drug design has led to several molecularly targeted medicines for drug-resistant or difficult-to-treat cancers.
| Harvey J BergerChairman/Pres/CEO | Timothy P ClacksonPresident:Research & Develpmnt |
| Edward M FitzgeraldExec VP/CFO/Treasurer | David L BersteinSenior VP/Chief Intellectual |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
APS News
-
Industry News
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page